Myriad Genetics Profit Margin 2006-2021 | MYGN
Current and historical gross margin, operating margin and net profit margin for Myriad Genetics (MYGN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Myriad Genetics net profit margin as of September 30, 2021 is -9.32%.
|Myriad Genetics Annual Profit Margins
|Myriad Genetics Quarterly Profit Margins
||Medical - Biomedical and Genetics
Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering innovative products that transform patients' lives. These products include leading molecular diagnostic tests for hereditary cancer, urological cancer, lung cancer, autoimmune disorders and other diseases. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Myriad's hereditary cancer genetic testing, which helps healthcare professionals better manage and tailor medical care. Myriad is expanding their reach and increasing their impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.